Impact of COVID-19 on Intratumoral Cancer Therapy Industry:
COVID-19 had a mixed impact on the intratumoral cancer therapy industry. Due to the lockdown restrictions and travel ban, it was difficult for the patients to get the therapy done. In the COVID- 19, there is a high chance for cancer patients to get infected because COVID 19 affects the patient's immune systems. However, continuous cancer intratumoral treatment processes for cancer patients are mandatory, and it enhances their immune system's ability to fight against COVID. Intratumoral therapy is a cancer treatment that boosts the human immune system to fight against cancer cells. Further, cancer patients require regular monitoring of the conditions, resulting in industry growth.
Although many factors propel the growth of the global intratumoral cancer therapy market, such as an increase in healthcare expenditure, a surge in access to medical insurance, a rise in the incidence of cancer, and a rise in technological advancements in cancer treatment therapies. According to this report the Worldwide Intratumoral Cancer Therapy Market Size was US$ 111.41 Billion in 2021.
Global Intratumoral Cancer Therapy Industry will grow at a CAGR of 11.4% from 2021-2027
Based on technology, the intratumoral cancer therapy industry includes Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and Others. The monoclonal antibody technology has the most significant growth in the previous year, owing to a surge in monoclonal antibodies for cancer immunotherapy. They exhibit different properties where the immune technique can be modulated, and thus they can activate or inhibit the molecules targeted on the immune system. Additionally, monoclonal antibodies also generate the antitumor immune response. There are various monoclonal antibodies, such as naked, conjugated, and bispecific monoclonal antibodies.
In terms of application, cancer intratumoral therapy is used to treat various cancer applications like Colorectal Cancer, Melanoma, Prostate Cancer, Lung Cancer, Breast Cancer, Head & Neck Cancer, and others. Lungs cancer had the most consequential market. Owing to the high incidence of lung cancer globally and the surge in the awareness program regarding the need for early lung cancer therapeutics. The U.S. food and drug administration has authorized Tabrecta (Capmatinib) to regale non-small cell lung cancer in 2020.
North America holds a Considerable Cancer Intratumoral Therapy Market Worldwide
Geographically, North America held a considerable global cancer intratumoral therapy market. Rising accessibility to current therapy and increasing cancer disease incidence, combined with a growing senior population, lead to regional market development. Recently, U.S. food and administration has supported 32 various immunotherapies to treat 20 cancer diseases, including immunomodulators, cell-based immunotherapies, BCG vaccines, targeted therapies, and oncotic viruses.
The Asia Pacific is to experience the fastest growth owing to a rise in healthcare expenditure, the surge in per capita income, and improvement in healthcare infrastructure. Countries like China and Japan are introducing new and sophisticated immunotherapy medications. These countries have clinical trials for new drug molecules, alternative treatments, and FDA approval.
Key Market Players:
The major players operating in the global intratumoral cancer therapy market include Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novarts AG, Johnson & Johnson, Eli Lily Company, F. Hoffmann-la Roche Ltd, Seattle Genetics Inc.
This research report titled “Intratumoral Cancer Therapy Market, Global Forecast, by Application (Colorectal Cancer, Melanoma, Prostate Cancer, Lung Cancer, Breast Cancer, Head & Neck Cancer, and others), Technology Type (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and Others), End Users (Hospital, Cancer Research Centres, Clinical), Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novarts AG, Johnson & Johnson, Eli Lily Company, F. Hoffmann-la Roche Ltd, Seattle Genetics Inc)” provides a complete analysis of Global Intratumoral Cancer Therapy Industry
Application - Market has been covered from 7 viewpoints
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head & Neck Cancer
- Others
Technology Type - Market has been covered from 6 viewpoints
- Monoclonal Antibodies
- Vaccines
- Checkpoint Inhibitors
- Cell Therapies
- Immune System Modulators
- Adoptive Cell Transfer
- Cytokines
- Others
End Users - Market has been covered from 3 viewpoints
- Hospital
- Cancer Research Centres
- Clinical
Regions - Market has been covered from 5 viewpoints
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Company Insights:
- Overview
- Initiatives & Strategy
- Revenue
Companies Covered in the Report:
- Amgen Inc
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- Pfizer Inc
- Novarts AG
- Johnson & Johnson
- Eli Lily Company
- F. Hoffmann-la Roche Ltd
- Seattle Genetics Inc
- Novartis International AG
- Merck & Co. Inc.
- Amgen Inc.
Table of Contents
Companies Mentioned
- Amgen Inc
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- Pfizer Inc
- Novarts AG
- Johnson & Johnson
- Eli Lily Company
- F. Hoffmann-la Roche Ltd
- Seattle Genetics Inc
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 172 |
Published | February 2022 |
Forecast Period | 2021 - 2027 |
Estimated Market Value ( USD | $ 111.41 Billion |
Forecasted Market Value ( USD | $ 212.92 Billion |
Compound Annual Growth Rate | 11.4% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |